Standout Papers

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6):... 2012 2026 2016 2021 451
  1. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study (2012)
    John B. Buse, Michael A. Nauck et al. The Lancet

Immediate Impact

2 by Nobel laureates 5 from Science/Nature 119 standout
Sub-graph 1 of 20

Citing Papers

A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
2024 Standout
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
2024 Standout
33 intermediate papers

Works of Marilyn K. Boardman being referenced

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
2012 Standout
Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)
2011
and 5 more

Author Peers

Author Last Decade Papers Cites
Marilyn K. Boardman 1004 460 351 11 1.1k
Julie Derving Karsbøl 1049 721 269 15 1.2k
Ken Wilhelm 856 362 328 7 930
Lisbeth V. Jacobsen 935 384 363 24 1.2k
Cory R. Heilmann 1024 564 392 19 1.4k
Shizuka Kaneko 799 385 278 22 962
Richard W Simpson 673 341 226 18 949
P. Miossec 971 446 372 22 1.1k
Susan Johnson 718 362 294 25 952
Ted Okerson 829 353 463 21 1.0k
Mario Widel 749 422 272 7 901

All Works

Loading papers...

Rankless by CCL
2026